Tuesday 26 December 2017

Protein Engineering Market worth $1,463.0 Million by 2020

The protein engineering market is expected to grow at a double–digit CAGR of 15.7% to reach $1,463.0 million by 2020 from $705.5 million in 2015. Major factors fueling market growth are the increase in adoption of protein drugs over non-protein drugs, high prevalence rate of lifestyle diseases, growth in funding for protein engineering, and reduction in overall timeline and cost for drug discovery. However, expensive and high maintenance tools and instruments used in protein engineering and dearth of trained personnel are restricting the growth of the market.


This market is broadly segmented into instrument, reagent and services and software, by product. On the basis of technology the market is segmented into rational protein design, and irrational protein design. Rational protein design emerged as highly adopted technology in protein engineering market in 2014.

Based on protein type, the market is categorized into monoclonal antibodies, insulin, erythropoietin, interferon, colony stimulating factor, growth hormones, coagulation factor, vaccines and others (interleukins, follicle stimulating hormones, enzyme replacement). Monoclonal antibodies is the largest as well as fastest growing segment of the protein engineering protein type market.

Based on end user, the protein engineering market is broadly classified into academic research institutes, pharmaceutical and biotechnology companies and contract research organizations. Pharmaceutical and biotechnology companies is the largest and fastest-growing end user segment. The high growth rate of this market can be attributed to technological advancements in protein engineering and the increase in R&D budgets in the pharmaceutical sector.

Geographically, this market is dominated by North America, followed by Europe. Asia is expected to be the fastest growing region during the forecast period.


Key players operating in this market are AB-Sciex (U.S.),  Agilent Technologies (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Bruker Corp. (U.S.), , GE Healthcare (U.K.), Perkin Elmer (U.S.), Sigma-Aldrich Corp. (U.S.), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S).

No comments:

Post a Comment